The University of Southampton
University of Southampton Institutional Repository

Cost-utility analysis of molnupiravir plus usual care versus usual care alone as early treatment for community-based adults with COVID-19 and increased risk of adverse outcomes in the UK PANORAMIC trial

Cost-utility analysis of molnupiravir plus usual care versus usual care alone as early treatment for community-based adults with COVID-19 and increased risk of adverse outcomes in the UK PANORAMIC trial
Cost-utility analysis of molnupiravir plus usual care versus usual care alone as early treatment for community-based adults with COVID-19 and increased risk of adverse outcomes in the UK PANORAMIC trial

Background: the cost-effectiveness of molnupiravir, an oral antiviral for early treatment of SARS-CoV-2, has not been established in vaccinated populations.

Aim: to evaluate the cost-effectiveness of molnupiravir relative to usual care alone among mainly vaccinated community-based people at higher risk of severe outcomes from COVID-19 over six months.

Design and setting: economic evaluation of the PANORAMIC trial in the UK.

Method: a cost-utility analysis that adopted a UK National Health Service and personal social services perspective and a six-month time horizon was performed using PANORAMIC trial data. Cost-effectiveness was expressed in terms of incremental cost per quality-adjusted life year (QALY) gained. Sensitivity and subgroup analyses assessed the impacts of uncertainty and heterogeneity. Threshold analysis explored the price for molnupiravir consistent with likely reimbursement.

Results: in the base case analysis, molnupiravir had higher mean costs of £449 (95% confidence interval [CI] 445 to 453) and higher mean QALYs of 0.0055 (95% CI 0.004 to 0.007) than usual care (mean incremental cost per QALY of £81190). Sensitivity and subgroup analyses showed similar results, except those aged ≥75 years with a 55% probability of being cost-effective at a £30000 per QALY threshold. Molnupiravir would have to be priced around £147 per course to be cost-effective at a £15000 per QALY threshold.

Conclusion: molnupiravir at the current cost of £513 per course is unlikely to be cost-effective relative to usual care over a six-month time horizon among mainly vaccinated COVID-19 patients at increased risk of adverse outcomes, except those aged ≥75 years.

0960-1643
Png, May Ee
ebb739c2-b3ab-483c-8d5a-1cef01799afa
Harris, Victoria
b6d6e7b3-9a3b-48ea-a506-aa6716d5f973
Grabey, Jenna
ae75693d-6da5-4834-bdcb-771ec029c256
Hart, Nigel David
54bd7c70-5505-4aa8-8997-8397149500b0
Jani, Bhautesh Dinesh
9f519f10-405c-44e5-bf8d-722a4dad24ad
Butler, Daniel
8172594e-49d9-4ac1-8a76-f481459bd35e
Carson-Stevens, Andrew
d34901f8-fbac-4921-8bf2-dfb1fe81512b
Coates, Maria
4bece266-f962-40a0-8289-cfa22c3a9d1c
Cureton, Lucy
5ac89f43-805b-4973-b303-a0b017e667b0
Dobson, Melissa
30b8369c-22ae-41b4-8747-8e83181b3585
Dorward, Jienchi
4bf66901-771f-4d52-bb9d-bf3fda2fb272
Evans, Philip
7bd91706-f249-471d-be68-e1a33d95b6b6
Francis, Nick
9b610883-605c-4fee-871d-defaa86ccf8e
Gbinigie, Oghenekome Abisoye
8d4ff434-0535-4f56-8465-feccafe1247b
Hayward, Gail
91362d6f-3c3b-4eae-8fc8-1571ccf184c1
Holmes, Jane
cae8db15-fb4a-473f-a5f8-5008dc4c8991
Hood, Kerenza
dbabde72-de16-41ed-80e6-ad91791469ab
Khoo, Saye
4ad67fee-e6a4-43d2-b7a8-5920d718f568
Ahmed, Haroon
880dac61-6070-4e31-9d09-ed7dbbf9a5cf
Lown, Mark
4742d5f8-bcf3-4e0b-811c-920e7d010c9b
Mckenna, Micheal
c29c18b6-7563-402d-90e5-1020806eb903
Mort, Sam
d88c662b-4f32-41d2-b11f-560f8e0ea6ff
Nguyen-Van-Tam, Jonathan
489ea2ed-2c0b-435b-88f1-ebfaffed800f
Rahman, Najib
16ffac72-7f1b-4ae1-9641-2ed9a96c71d8
Richards, Duncan B
b9c1e85c-05e6-48c9-86c6-566602955af0
Thomas, Nicholas
1218f8d6-787a-4b0a-9603-7c831563a9d7
van Hecke, Oliver
2e5330f6-842a-4b1e-9f89-f30dabe4580f
Hobbs, Fd Richard
2e48ac78-1c66-4738-844b-a0ea0cb85d6f
Little, Paul
1bf2d1f7-200c-47a5-ab16-fe5a8756a777
Yu, Ly-Mee
bc6ca332-bffb-4836-80e9-c427dca12c19
Butler, Christopher C
8bf4cace-c34a-4b65-838f-29c2be91e434
Petrou, Stavros
5ee930f5-99db-4fb8-b401-95584cff0e20
et al.
Png, May Ee
ebb739c2-b3ab-483c-8d5a-1cef01799afa
Harris, Victoria
b6d6e7b3-9a3b-48ea-a506-aa6716d5f973
Grabey, Jenna
ae75693d-6da5-4834-bdcb-771ec029c256
Hart, Nigel David
54bd7c70-5505-4aa8-8997-8397149500b0
Jani, Bhautesh Dinesh
9f519f10-405c-44e5-bf8d-722a4dad24ad
Butler, Daniel
8172594e-49d9-4ac1-8a76-f481459bd35e
Carson-Stevens, Andrew
d34901f8-fbac-4921-8bf2-dfb1fe81512b
Coates, Maria
4bece266-f962-40a0-8289-cfa22c3a9d1c
Cureton, Lucy
5ac89f43-805b-4973-b303-a0b017e667b0
Dobson, Melissa
30b8369c-22ae-41b4-8747-8e83181b3585
Dorward, Jienchi
4bf66901-771f-4d52-bb9d-bf3fda2fb272
Evans, Philip
7bd91706-f249-471d-be68-e1a33d95b6b6
Francis, Nick
9b610883-605c-4fee-871d-defaa86ccf8e
Gbinigie, Oghenekome Abisoye
8d4ff434-0535-4f56-8465-feccafe1247b
Hayward, Gail
91362d6f-3c3b-4eae-8fc8-1571ccf184c1
Holmes, Jane
cae8db15-fb4a-473f-a5f8-5008dc4c8991
Hood, Kerenza
dbabde72-de16-41ed-80e6-ad91791469ab
Khoo, Saye
4ad67fee-e6a4-43d2-b7a8-5920d718f568
Ahmed, Haroon
880dac61-6070-4e31-9d09-ed7dbbf9a5cf
Lown, Mark
4742d5f8-bcf3-4e0b-811c-920e7d010c9b
Mckenna, Micheal
c29c18b6-7563-402d-90e5-1020806eb903
Mort, Sam
d88c662b-4f32-41d2-b11f-560f8e0ea6ff
Nguyen-Van-Tam, Jonathan
489ea2ed-2c0b-435b-88f1-ebfaffed800f
Rahman, Najib
16ffac72-7f1b-4ae1-9641-2ed9a96c71d8
Richards, Duncan B
b9c1e85c-05e6-48c9-86c6-566602955af0
Thomas, Nicholas
1218f8d6-787a-4b0a-9603-7c831563a9d7
van Hecke, Oliver
2e5330f6-842a-4b1e-9f89-f30dabe4580f
Hobbs, Fd Richard
2e48ac78-1c66-4738-844b-a0ea0cb85d6f
Little, Paul
1bf2d1f7-200c-47a5-ab16-fe5a8756a777
Yu, Ly-Mee
bc6ca332-bffb-4836-80e9-c427dca12c19
Butler, Christopher C
8bf4cace-c34a-4b65-838f-29c2be91e434
Petrou, Stavros
5ee930f5-99db-4fb8-b401-95584cff0e20

Png, May Ee, Harris, Victoria and Grabey, Jenna , et al. (2024) Cost-utility analysis of molnupiravir plus usual care versus usual care alone as early treatment for community-based adults with COVID-19 and increased risk of adverse outcomes in the UK PANORAMIC trial. The British journal of general practice : the journal of the Royal College of General Practitioners. (doi:10.3399/BJGP.2023.0444).

Record type: Article

Abstract

Background: the cost-effectiveness of molnupiravir, an oral antiviral for early treatment of SARS-CoV-2, has not been established in vaccinated populations.

Aim: to evaluate the cost-effectiveness of molnupiravir relative to usual care alone among mainly vaccinated community-based people at higher risk of severe outcomes from COVID-19 over six months.

Design and setting: economic evaluation of the PANORAMIC trial in the UK.

Method: a cost-utility analysis that adopted a UK National Health Service and personal social services perspective and a six-month time horizon was performed using PANORAMIC trial data. Cost-effectiveness was expressed in terms of incremental cost per quality-adjusted life year (QALY) gained. Sensitivity and subgroup analyses assessed the impacts of uncertainty and heterogeneity. Threshold analysis explored the price for molnupiravir consistent with likely reimbursement.

Results: in the base case analysis, molnupiravir had higher mean costs of £449 (95% confidence interval [CI] 445 to 453) and higher mean QALYs of 0.0055 (95% CI 0.004 to 0.007) than usual care (mean incremental cost per QALY of £81190). Sensitivity and subgroup analyses showed similar results, except those aged ≥75 years with a 55% probability of being cost-effective at a £30000 per QALY threshold. Molnupiravir would have to be priced around £147 per course to be cost-effective at a £15000 per QALY threshold.

Conclusion: molnupiravir at the current cost of £513 per course is unlikely to be cost-effective relative to usual care over a six-month time horizon among mainly vaccinated COVID-19 patients at increased risk of adverse outcomes, except those aged ≥75 years.

Text
BJGP.2023.0444.full - Version of Record
Available under License Creative Commons Attribution.
Download (485kB)

More information

Accepted/In Press date: 20 November 2023
e-pub ahead of print date: 16 January 2024
Published date: 16 January 2024
Additional Information: For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.

Identifiers

Local EPrints ID: 486410
URI: http://eprints.soton.ac.uk/id/eprint/486410
ISSN: 0960-1643
PURE UUID: 0c1ceecb-97ea-4920-849d-3626edb3a7d0
ORCID for Nick Francis: ORCID iD orcid.org/0000-0001-8939-7312
ORCID for Mark Lown: ORCID iD orcid.org/0000-0001-8309-568X

Catalogue record

Date deposited: 19 Jan 2024 18:47
Last modified: 18 Apr 2024 01:57

Export record

Altmetrics

Contributors

Author: May Ee Png
Author: Victoria Harris
Author: Jenna Grabey
Author: Nigel David Hart
Author: Bhautesh Dinesh Jani
Author: Daniel Butler
Author: Andrew Carson-Stevens
Author: Maria Coates
Author: Lucy Cureton
Author: Melissa Dobson
Author: Jienchi Dorward
Author: Philip Evans
Author: Nick Francis ORCID iD
Author: Oghenekome Abisoye Gbinigie
Author: Gail Hayward
Author: Jane Holmes
Author: Kerenza Hood
Author: Saye Khoo
Author: Haroon Ahmed
Author: Mark Lown ORCID iD
Author: Micheal Mckenna
Author: Sam Mort
Author: Jonathan Nguyen-Van-Tam
Author: Najib Rahman
Author: Duncan B Richards
Author: Nicholas Thomas
Author: Oliver van Hecke
Author: Fd Richard Hobbs
Author: Paul Little
Author: Ly-Mee Yu
Author: Christopher C Butler
Author: Stavros Petrou
Corporate Author: et al.

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×